TTrialPathMatch Me to Trials
← Back to trials
RecruitingProstate CarcinomaStage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Eligible age

18+ yrs

Accepts

Men

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types of androgen ablation therapy given in this study: AAP + ADT and Apa + ADT. AAP + ADT is the treatment combination of the drugs abiraterone acetate and prednisone (AAP) given with androgen deprivation therapy (ADT, also known as androgen deprivation therapy or androgen suppression medication, which is used as standard of care to lower testosterone levels in men with high risk localized or metastatic prostate cancer). Apa + ADT is the treatment combination of the drug apalutamide (Apa) given with ADT. Androgen ablation therapy with or without niraparib after radiation therapy may help to control the disease in patients with prostate cancer.

Sponsor: M.D. Anderson Cancer Center

You may qualify if…

  • ✓ Completion of informed consent prior to any study specific procedures. Consent may be done remotely.
  • ✓ Patients must agree to tissue collection for correlative studies at the specified timepoints
  • ✓ Male aged 18 years and above
  • ✓ Histologically or cytologically confirmed prostate carcinoma
  • ✓ Localized or regional high-risk disease as defined by at least one of the following features: Prostate specific antigen (PSA) \> 20 ng/mL, T3a or higher, grade group 4-5 (i.e. Gleason score ≥ 8) as per National Comprehensive Cancer Network (NCCN) Prostate Cancer Version 2.2020 for high risk or very high risk prostate cancer, and/or regional lymph nodes positive for prostate cancer
  • ✓ Planned for definitive treatment of local regional prostate cancer using XRT and androgen ablation
  • ✓ Willing to undergo ongoing medical castration to maintain testosterone levels of ≤ 50 ng/dL (≤ 2.0 nM) throughout systemic treatment or have undergone bilateral orchiectomy
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2. Patients must have adequate organ and bone marrow function measured within 7 days prior to treatment registration as defined below:

You may not qualify if…

  • ✕ Any prior systemic treatment for prostate cancer with the exception of ADT started within 6 months of trial enrollment. Any prior PARP inhibitor therapy
  • ✕ Patients who have prostate cancer with distant metastatic disease
  • ✕ Patients who have had prior major surgery (prostatectomy) or radiotherapy for the treatment of prostate cancer
  • ✕ Any unresolved toxicity (Common Terminology Criteria for Adverse Events \[CTCAE\] grade ≥ 2) from previous anti-cancer therapies
  • ✕ History or current diagnosis of MDS/AML, and/or history of any malignancy \[other than the one treated in this study\] which has a ≥ 30% probability of recurrence within 24 months (except for adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix or Ta urothelial carcinomas)
  • ✕ Active uncontrolled infection (patients completing a course of antibiotic or antiviral therapy whose infection is deemed to be controlled may be allowed on study after discussion with the principal investigator \[PI\]; the PI will serve as the final arbiter regarding eligibility)
  • ✕ Active or symptomatic viral hepatitis or chronic liver disease
  • ✕ Active pneumonitis or extensive bilateral lung disease of non-malignant etiology

Where it's recruiting

Texas

Houston

Source: ClinicalTrials.gov · NCT04947254 · last updated 2026-06-23